Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019033123) DRUG COMBINATIONS FOR TARGETING MULTIPLE MUTATIONS IN CANCER
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/033123 International Application No.: PCT/US2018/046570
Publication Date: 14.02.2019 International Filing Date: 13.08.2018
IPC:
C12Q 1/68 (2018.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids
Applicants:
CUREMATCH, INC. [US/US]; 6370 Lusk Blvd., Suite F208 San Diego, CA 92121, US
Inventors:
TSIGELNY, Igor, Flint; US
BOICHARD, Amelie, Clemence; US
BUSH, Kevin, Toivo; US
Agent:
BUCKLEY, Kevin; US
Priority Data:
62/544,69311.08.2017US
Title (EN) DRUG COMBINATIONS FOR TARGETING MULTIPLE MUTATIONS IN CANCER
(FR) ASSOCIATIONS DE MÉDICAMENTS POUR LE CIBLAGE DE MULTIPLES MUTATIONS DANS LE CANCER
Abstract:
(EN) Disclosed are methods for treating a cancer in a patient. The method comprises: (a) defining a set of substances targeting pathogenic genes identified by screening of a sample of cancer cells from a patient by NGS or other technique, (b) identifying two or more target genes in the cancer cells, each of which containing an actionable mutation and (c) testing, using in vitro culture cell experiments, the efficacy of one or more substances (administered sequentially or concurrently) targeting the actionable mutation for each of the two or more target genes identified and (d) designating potential efficacious therapeutic options that will be used to treat the patient's cancer.
(FR) La présente invention concerne des méthodes de traitement d'un cancer chez un patient. La méthode comprend : (a) la définition d'un ensemble de substances ciblant des gènes pathogènes identifiés par criblage dans un échantillon de cellules cancéreuses provenant d'un patient par NGS ou autre technique, (b) l'identification d'au moins deux gènes cibles dans les cellules cancéreuses, contenant chacun une mutation actionnable, (c) le test, par expérimentation en culture cellulaire in vitro, de l'efficacité d'une ou de plusieurs des substances (administrées de manière séquentielle ou simultanée) ciblant la mutation actionnable pour chacun des deux gènes cibles ou plus qui ont été identifiés et (d) la désignation d'options thérapeutiques efficaces potentielles qui seront utilisées pour traiter le cancer du patient.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)